Leading Sites

Category

University of Iowa Hospitals and Clinics Activated as Site for REGN-COV2 Clinical Trial Targeting COVID-19

Clinical investigators at University of Iowa Hospitals and Clinics (UIHC) are participating in a Phase 3 clinical trial investigating Regeneron’s novel monoclonal antibody targeting COVDI-19 known as REGN-COV2. TrialSite News recently showcased this rapidly developed...

Houston’s Largest Privately Owned Clinical Investigator Network Activated by German BioNTech for COVID-19 Vaccine Trials

Houston, a vast and sprawling but certainly dynamic place also happens to be America’s fourth largest city known as an international hub of medicine and energy, and represents an important hub in the war on COVID-19. Thus a Houston research firm, actually part of a...

Cincinnati Children’s Hospital Conducting Phase I/II Clinical Trial Investigating BNT 162 COVID-19 Vaccine

Representing one of four sites across the United States, principal investigator and former Naval Officer Dr. Robert Frenck at Cincinnati Children’s Hospital is leading the Phase I/2 trials investigating the BNT 162 COVID-19 vaccine. Developed by a German biotech...

Lost Time can Mean Lost Lives: Researchers and Patients Thankful as Lab Research Resumes

For some individuals with congestive heart failure, the COVID-19 shutdowns couldn’t have come at a worse time as many research centers had to temporarily halt studies. This put some patients at great risk. In one case, a patient named Brendle Miller found an active...

Top Oncology Investigator Dr. Anthony Tolcher (Next Oncology) Selected by Heat Biologics to Lead Novel Phase I Oncology Study

Anthony Tolcher, MD, FRCPC, a medical oncologist and co-founder of research organization NEXT Oncology has been appointed the lead investigator for a Phase I clinical trial investigating Heat Biologics’ investigational therapy called PTX-35, a novel potential...

University of Cincinnati Selected by NIAID as Phase III Clinical Trial Site for mRNA-1273 COVID-19 Vaccine

The University of Cincinnati (UC) has been selected by the National Institute of Allergy and Infectious Diseases (NIAID) as a clinical investigational site for the pivotal Phase III clinical trial evaluating the effectiveness of Moderna’s mRNA-1273 COVID-19...

Pin It on Pinterest